Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Mereo BioPharma Group plcNASDAQ: MREO

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital turns positive

Q1 FY2026 other working capital was $298.5K, compared with -$1.83M a year earlier. Trailing-twelve-month other working capital was $562.58K.

Context

  • Other working capital amounted to 645.7% of revenue in FY2025.
  • Other working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other working capital holds near $298.5K or moves back toward the trailing-twelve-month quarterly average of $140.64K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$298.5K+113.4% QoQ
Last fiscal yearDec 2025
-$3.23M-384.7% YoY
LTMMar 2026
$562.58K+511.5% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+116.3%——
1 year-384.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(3.23M) USD
Year-over-year change
-384.7%

Other Working Capital vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +511.5% is the 3rd highest of 10, against a peer median of -105.7%.
  • Other working capital amounts to 112.5% of revenue for MREO, versus a peer median of 134.3%.
MREO Competitors
Other Working Capital for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$12.15M USD+749.2%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$8.69M USD-1032.5%+70.8%—
SLNSilence Therapeutics plcLTM Mar 2026$8.34M USD——905.3%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$7.32M USD-220.8%-47.2%—
IMMPImmutep LimitedFY2025A$6.02M AUD-311.0%+56.9%119.5%
ACIUAC Immune S.A.LTM Dec 2025CHF 5.33M CHF-105.7%-9.1%149.2%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.17M USD-100.0%——
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.55M USD+2140.6%+2.7%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-122.5%+26.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$562.58K USD+511.5%—112.5%
Peer median (excluding MREO) —-105.7%+26.3%134.3%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.